Healthcarenews16 Apr, 2024Business
According to research report the global minimal residual disease testing market is projected to reach USD 2.3 Billion by 2027, at a CAGR of 14.0%. Increasing prevalence of cancer and hematological malignancies, rising initiatives undertaken by government bodies to create awareness about cancer, and increasing collaborations are factors driving the growth of the global minimal residual disease testing market. Emerging economies such as China, Japan, and India are providing lucrative opportunities for the players operating in the minimal residual disease testing market. The major players operating in this market are Labcorp Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Guardant Health (US), Sysmex Corporation (Japan), NeoGenomics Laboratories, Inc. (US), Adaptive Biotechnologies Corporation (US), ArcherDX, Inc.
Tractor Lights
Batteries Plus Franchise
Jeyakumar Savarimuthu
Best Trash Junk Removal & Demo
Fun88 203
Garage Builders Seattle
4skarate
Game ??i Th??ng
Lucky88 Vip
Raby It